Dennis O’Neill, President, Bio-Kai
CEOCFO Magazine interviews Bio-Kai President Dennis O’Neill on their 100% Organic, non-GMO Astaxanthin
FREMONT, CALIFORNIA, US, July 13, 2021 /EINPresswire.com/ — CEOCFO Magazine, an independent business and investor publication that highlights important technologies and companies, today announced an interview with Dennis O’Neill, President of Bio-Kai, a 100% organic, non-GMO astaxanthin, biosynthetic astaxanthin company, producing astaxanthin for the salmon, poultry and cattle industries, headquartered in Fremont, California. “We solve a major problem for the fish-feed market which means that they need to get off of synthetic products and that is being demanded by the grocery stores that carry these products.” Asked what is Bio-Kai, Mr. O’Neill told CEOCFO’s Senior Editor Lynn Fosse, “Bio-Kai is a biosynthesis platform that biosynthesis a compound called astaxanthin which is used for animal feed and is also is used in human consumption market because it is 550 times stronger than vitamin E as an antioxidant, 550 times stronger than green tea, 800 times stronger than CoQ10 and 6000 times stronger than vitamin C.”
Mr. O’Neill told us about the origins of Bio-Kai and how they got into the astaxanthin market; “What happened was that this is a spinoff company from a company called Biomedican which is in the cannabinoid market. One of our investors said that we should diversify outside of cannabinoids so we looked for what was the best compound we could diversify outside. We found astaxanthin as being that product. We spun-off the astaxanthin as being its own company because the people that buy astaxanthin are really not that interested in cannabinoids and people that buy cannabinoids are really not that interested in astaxanthin.”
In the interview Mr. O’Neill explained the advantage their product offers, “What we offer is a 99% pharmaceutical grade bioorganic compound that has zero toxins or contaminates. It is the exact same product every single time and we can sell it at a price of the synthetic. The advantage here is the largest buyer of astaxanthin for fish farms, they can get an organic product instead of a synthetic product for the same price. All the major grocery stores like Wholefoods and all these major chains are looking for products that have no synthetics in them. So for that is the reason we believe that we are going to be able to replace all the synthetic products in the market which is about $150 million right now, with an organic product.” Mr. O’Neill continues defining the market, “Right now, the astaxanthin market is a billion-dollar marketplace and I would say about 80% or maybe 85% is in the fish-feed space. The balance of it is in human consumption but that is growing exponentially now due to the health benefits. The reason why we went into the fish feed market first is because this is the largest percentage of the market that we could disrupt in a significant way… Probably 98% of these feeds are using a synthetic product.”
Explaining how they produce their astaxanthin, Mr. O’Neill told CEOCFO, “We are producing Astaxanthin in the process similar to what people use for brewing beer or making wine. We are taking water, sugar and yeasts and fermentation for several days. During fermentation our yeasts are producing Astaxanthin instead of alcohol. On the next step we are extracting Astaxanthin from the mixture. We are able to purify Astaxanthin to 98+% purity. This is why our product is suitable to the highest standards of human consumption – pharmaceutical grade purity.”
Mr. O’Neill emphasized, “Our product is Organic and Non-GMO because for human consumption we are planning to use Organic, Non-GMO sugar as a starting material. We are not using any antibiotics or pesticides. And we are purifying our product to remove any traces of DNA, which is easy to do for compounds like Astaxanthin.”
Discussing where they are in development and production, Mr. O’Neill said, “We are already in pilot scale production, so we have been providing samples to large global buyers. We are now raising capital to go into large scale production and we may do some contract manufacturing initially just to get the product into the market as quickly as possible but ultimately, we will be building our own facilities in multiple geographic areas to supply the market.”
For more information:
Contact:
Dennis O’Neill, President
Dennis@biomedican.com
Lynn Fosse, Senior Editor
CEOCFO Magazine
+1 352-431-3400
email us here
